J. Larkin

发表

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

K. Kerr, S. Peters, J. Haanen, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma

P. Ascierto, R. Dummer, J. Wolchok, 2022, Cancers.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

K. Kerr, S. Peters, J. Haanen, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series

J. McQuade, Douglas B. Johnson, G. Long, 2022, Melanoma research.

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

J. Utikal, S. Haferkamp, D. Schadendorf, 2019, European journal of cancer.

Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''

M. Millward, G. McArthur, G. Long, 2017, British Journal of Cancer.

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.

D. Schadendorf, R. Dummer, J. Wolchok, 2022, Journal of Clinical Oncology.

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

A. Hauschild, D. Schadendorf, R. Dummer, 2020, The New England journal of medicine.

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.

P. Ascierto, A. Arance, P. Queirolo, 2022, European journal of cancer.

789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study)

J. Kirkwood, P. Hari, H. Kluger, 2022, Regular and Young Investigator Award Abstracts.

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

L. Pickering, Douglas B. Johnson, C. Blank, 2022, European journal of cancer.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

A. Ribas, C. Blank, A. Arance, 2017, The Lancet.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

J. Utikal, A. Hauschild, D. Schadendorf, 2015, The Lancet.

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma

D. Schadendorf, D. Jackson, P. Ascierto, 2021, Cancer Immunology Research.

Immune checkpoint inhibitors in melanoma

G. Long, M. Carlino, J. Larkin, 2021, The Lancet.

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2017, The New England journal of medicine.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.

D. Schadendorf, R. Dummer, J. Wolchok, 2021 .

Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

M. Weichenthal, J. Utikal, D. Schadendorf, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.

Douglas B. Johnson, G. Long, O. Michielin, 2021, European journal of cancer.

Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy.

P. Ascierto, Douglas B. Johnson, G. Long, 2021, European journal of cancer.

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

P. Ascierto, A. Ribas, C. Garbe, 2021, Clinical Cancer Research.

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.

A. Hauschild, D. Schadendorf, K. Flaherty, 2020, The Lancet. Oncology.

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials

A. Hauschild, D. Schadendorf, P. Ascierto, 2014, Journal of Translational Medicine.

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Michael E. Egger, J. Kirkwood, P. Hari, 2022, Journal for ImmunoTherapy of Cancer.

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.

J. Kirkwood, H. Kluger, K. Lewis, 2021, Journal of Clinical Oncology.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

K. Kerr, S. Peters, J. Haanen, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2019, The Lancet. Oncology.

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

D. Schadendorf, P. Ascierto, R. Dummer, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

D. Schadendorf, S. Puig, P. Ascierto, 2022, European journal of cancer.

Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al

P. Ascierto, M. Mandalà, J. Weber, 2022, Journal for ImmunoTherapy of Cancer.

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

P. Ascierto, M. Del Vecchio, M. Mandalà, 2021, Journal for ImmunoTherapy of Cancer.

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

A. Hauschild, S. Puig, R. Fisher, 2021, European journal of cancer.

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2021, Clinical Trials.

Corrections to "Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

K. Kerr, S. Peters, J. Haanen, 2018 .

Hitting the sweet spot: optimal use of corticosteroids for immune checkpoint inhibitor side-effects.

L. Spain, A. Schmitt, J. Larkin, 2022, The Lancet. Oncology.

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

M. Millward, G. McArthur, G. Long, 2016, British Journal of Cancer.

Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).

R. Scolyer, E. Rozeman, C. Blank, 2017 .

How have immune checkpoint inhibitors transformed melanoma treatment?

A. Schmitt, J. Larkin, 2023, Trends in Urology & Men's Health.

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.

D. Schadendorf, P. Ascierto, A. Eggermont, 2022, NEJM evidence.

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

D. Schadendorf, P. Ascierto, C. Blank, 2023, European journal of cancer.

Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids.

A. Schmitt, A. Furness, J. Larkin, 2023, European journal of cancer.

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study

A. Hauschild, P. Ascierto, J. Larkin, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

A. Hauschild, K. Flaherty, P. Ascierto, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401

P. Ascierto, R. Dummer, M. Del Vecchio, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.

R. Scolyer, E. Rozeman, C. Blank, 2019, Journal of Clinical Oncology.

Symptomatic melanoma CNS metastases in the TRICOTEL study.

A. Schmitt, J. Larkin, 2022, The Lancet. Oncology.

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).

D. Schadendorf, P. Ascierto, E. Lipson, 2023, Journal of Clinical Oncology.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

P. Ascierto, A. Arance, P. Queirolo, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.

P. Ascierto, Douglas B. Johnson, G. Long, 2018 .

Comment on ‘Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'—Methodological challenges in combining miRNAs as circulating biomarkers

M. Gariboldi, M. Millward, G. McArthur, 2016, British Journal of Cancer.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

S. Peters, J. Haanen, C. Robert, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

P. Ascierto, M. Sznol, H. Gogas, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

James R. Anderson, R. Dummer, J. Larkin, 2018 .

Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

A. Ribas, J. Schachter, J. Grob, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.